The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Nov. 28, 9:05 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #79. Imprimis Pharmaceuticals, Inc. Intellectual Property for Ophthalmic Compound Development Opportunity

Acquirer: Imprimis Pharmaceuticals, Inc. (IMMY)
Acquiree: Intellectual Property for Ophthalmic Compound Development Opportunity
Details: Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships and by utilizing the FDA 505(b)(2) development pathway, has announced it has acquired intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Imprimis believes this formulation has the potential to significantly impact the fast-growing $5 billion global cataract surgery drug market. The acquisition allows Imprimis to pursue the commercial development of certain proprietary innovations and also provides Imprimis with a preemptive right on additional Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities.

Imprimis Pharmaceuticals is an ophthalmology-focused pharmaceutical company focused on the development, production and sale of medications. Co. operates its business through several subsidiaries: ImprimisRx, an ophthalmology focused compounding business; Park Compounding, a custom compounding business focused on patient specific orders; and Surface Pharmaceuticals, Inc., an ocular surface disease-focused 505(b)(2) specialty pharmaceutical subsidiary.

Open the IMMY Page at The Online Investor »

Company Name: 
Harrow Health Inc
Website: 
www.imprimispharma.com
Sector: 
Drugs & Pharmaceuticals
 

Open the IMMY Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree IMMY Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 79 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.